BAXTER INTL INC's ticker is BAX and the CUSIP is 071813109. A total of 922 filers reported holding BAXTER INTL INC in Q1 2024. The put-call ratio across all filers is 0.60 and the average weighting 0.1%.
About BAXTER INTL INC
Baxter International Inc. is a global healthcare company that specializes in developing and manufacturing medical products and therapies. The company has a long history of innovation and has been at the forefront of developing life-saving treatments for patients around the world.
Baxter's product portfolio includes a wide range of medical devices, pharmaceuticals, and biotechnology products. The company's products are used in hospitals, clinics, and other healthcare settings to treat a variety of conditions, including hemophilia, immune disorders, kidney disease, and other chronic and acute medical conditions.
Baxter's commitment to innovation has helped the company maintain a strong position in the healthcare industry. The company invests heavily in research and development, and has a strong pipeline of new products in development.
Baxter's leadership team is also a key strength of the company. The CEO, José Almeida, has a strong track record of success in the healthcare industry, and has been instrumental in driving the company's growth and success.
Overall, Baxter International Inc. is a strong and innovative company that is well-positioned to continue delivering value to patients, healthcare providers, and investors alike. With a strong product portfolio, a commitment to innovation, and a talented leadership team, Baxter is a company that investors should keep an eye on in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $216,847 | -24.0% | 6,427 | -3.0% | 0.01% | -22.2% |
Q1 2024 | $285,160 | -4.4% | 6,627 | -13.5% | 0.01% | -10.0% |
Q4 2023 | $298,157 | +3.1% | 7,662 | +0.7% | 0.01% | -9.1% |
Q3 2023 | $289,264 | -17.1% | 7,612 | 0.0% | 0.01% | -15.4% |
Q2 2023 | $348,790 | +12.2% | 7,612 | 0.0% | 0.01% | +8.3% |
Q1 2023 | $310,730 | -15.6% | 7,612 | +5.9% | 0.01% | -25.0% |
Q4 2022 | $368,083 | -5.4% | 7,185 | 0.0% | 0.02% | -11.1% |
Q3 2022 | $389,000 | +8.1% | 7,185 | +28.6% | 0.02% | +12.5% |
Q2 2022 | $360,000 | -7.7% | 5,585 | +10.9% | 0.02% | +6.7% |
Q1 2022 | $390,000 | -6.0% | 5,035 | +4.1% | 0.02% | +7.1% |
Q4 2021 | $415,000 | +6.7% | 4,835 | 0.0% | 0.01% | -33.3% |
Q3 2021 | $389,000 | 0.0% | 4,835 | 0.0% | 0.02% | 0.0% |
Q2 2021 | $389,000 | -4.7% | 4,835 | 0.0% | 0.02% | -16.0% |
Q1 2021 | $408,000 | +5.2% | 4,835 | 0.0% | 0.02% | -3.8% |
Q4 2020 | $388,000 | -0.3% | 4,835 | 0.0% | 0.03% | -13.3% |
Q3 2020 | $389,000 | -6.5% | 4,835 | 0.0% | 0.03% | -14.3% |
Q2 2020 | $416,000 | +5.9% | 4,835 | 0.0% | 0.04% | -14.6% |
Q1 2020 | $393,000 | -2.7% | 4,835 | 0.0% | 0.04% | +24.2% |
Q4 2019 | $404,000 | +1.3% | 4,835 | +6.0% | 0.03% | -10.8% |
Q3 2019 | $399,000 | +7.0% | 4,560 | 0.0% | 0.04% | +8.8% |
Q2 2019 | $373,000 | +6.0% | 4,560 | 0.0% | 0.03% | -5.6% |
Q1 2019 | $352,000 | +17.3% | 4,560 | 0.0% | 0.04% | -5.3% |
Q4 2018 | $300,000 | -14.8% | 4,560 | 0.0% | 0.04% | +5.6% |
Q3 2018 | $352,000 | +4.5% | 4,560 | 0.0% | 0.04% | +16.1% |
Q2 2018 | $337,000 | +15.8% | 4,560 | 0.0% | 0.03% | -6.1% |
Q1 2018 | $291,000 | -1.4% | 4,560 | 0.0% | 0.03% | +3.1% |
Q4 2017 | $295,000 | +2.4% | 4,560 | 0.0% | 0.03% | -5.9% |
Q3 2017 | $288,000 | +4.3% | 4,560 | 0.0% | 0.03% | +6.2% |
Q2 2017 | $276,000 | +39.4% | 4,560 | +20.0% | 0.03% | +52.4% |
Q1 2017 | $198,000 | +482.4% | 3,800 | +400.0% | 0.02% | +425.0% |
Q4 2016 | $34,000 | -98.4% | 760 | -83.3% | 0.00% | -85.7% |
Q3 2016 | $2,171,000 | +938.8% | 4,560 | -1.3% | 0.03% | +12.0% |
Q2 2016 | $209,000 | -33.9% | 4,620 | 0.0% | 0.02% | -34.2% |
Q1 2015 | $316,000 | -6.8% | 4,620 | 0.0% | 0.04% | -5.0% |
Q4 2014 | $339,000 | +2.1% | 4,620 | 0.0% | 0.04% | 0.0% |
Q3 2014 | $332,000 | -0.6% | 4,620 | 0.0% | 0.04% | -2.4% |
Q2 2014 | $334,000 | -1.8% | 4,620 | 0.0% | 0.04% | -2.4% |
Q1 2014 | $340,000 | – | 4,620 | – | 0.04% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Soditic Asset Management LLP | 147,620 | $7,951,000 | 9.91% |
NUANCE INVESTMENTS, LLC | 5,429,702 | $292,444,000 | 6.51% |
Endurant Capital Management LP | 245,093 | $13,201,000 | 4.30% |
Veritas Asset Management LLP | 8,589,401 | $462,625,000 | 3.83% |
GENERATION INVESTMENT MANAGEMENT LLP | 11,876,040 | $639,644,000 | 3.80% |
Sivik Global Healthcare LLC | 120,000 | $6,463,000 | 3.59% |
KINGDON CAPITAL MANAGEMENT, L.L.C. | 480,500 | $25,880,000 | 3.31% |
Integral Health Asset Management, LLC | 300,000 | $16,158,000 | 3.14% |
Boothe Investment Group, Inc. | 89,078 | $4,798,000 | 3.11% |
Glenview Capital Management | 2,257,019 | $121,563,000 | 3.04% |